Höffler D, Koeppe P, Naumann E, Lang E, Sörgel F
Medizinische Klinik III, Städtische Kliniken Darmstadt, Germany.
Infection. 1991 Sep-Oct;19(5):324-7. doi: 10.1007/BF01645356.
As only insufficient knowledge about the dosage of teicoplanin in hemodialysis patients exists, a clinical trial was performed on 26 patients. An initial dose of 800 mg teicoplanin, followed by doses of 400 mg on day 8 and day 15, was administered. In addition to the common clinical parameters (fever, white blood cell count, C-reactive protein), the plasma concentrations of this substance were determined. The HLTterm was 159 +/- 35 h, the Vss 104 +/- 25 1/100 kg and the CLtot 5.3 +/- 1.3 ml/min. It could be shown that the dosage regimen mentioned above produced long-lasting and highly effective levels, sufficiently surpassing the MICs of the expected bacteria (streptococci and staphylococci). The easily administered substance showed no adverse side effects, based on clinical criteria. The above-mentioned therapy nearly always resulted in success according to clinical criteria. Therefore, and due to its easy administration, it seems advantageous to start treatment with teicoplanin in hemodialysis patients obviously suffering from bacterial infections.
由于目前关于替考拉宁在血液透析患者中的剂量的知识不足，因此对26例患者进行了一项临床试验。给予替考拉宁初始剂量800mg，随后在第8天和第15天各给予400mg。除了常见的临床参数（发热、白细胞计数、C反应蛋白）外，还测定了该物质的血浆浓度。半衰期为159±35小时，稳态分布容积为104±25ml/100kg，总清除率为5.3±1.3ml/min。结果表明，上述给药方案产生了持久且高效的血药浓度，足以超过预期细菌（链球菌和葡萄球菌）的最低抑菌浓度。根据临床标准，这种易于给药的物质未显示出不良反应。根据临床标准，上述治疗几乎总是成功的。因此，鉴于其易于给药，对于明显患有细菌感染的血液透析患者，开始使用替考拉宁治疗似乎具有优势。
